# Intralymphatic Immunotherapy in Increasing Doses, Substudy

> **NCT02975479** · PHASE2,PHASE3 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 40 (estimated)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** ALK Diluent
- **DRUG:** ALK Alutard SQ 5-grasses or ALK Alutard Birch

## Key facts

- **NCT ID:** NCT02975479
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-06-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-06-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975479, "Intralymphatic Immunotherapy in Increasing Doses, Substudy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02975479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*